CUPISCO trial approach extends progression-free survival for CUP patients

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Oct 21 / Springer Healthcare

CUPISCO trial approach extends progression-free survival for CUP patients

Oncology Solid Tumours Pan-tumour ESMO-2023

Description

CUPISCO trial investigator Professor Linda Mileshkin describes the progression-free survival benefit achieved with use of molecularly guided treatment versus standard chemotherapy for patients with cancer of unknown primary.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.